Allied Biotech (ROCO:1780) Other Current Receivables: NT$5.9 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1780 Allied Biotech Corp ROCO:1780
73 GF Score
Price NT$22.75
GF Value NT$21.28
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Allied Biotech Other Current Receivables?

Allied Biotech ROCO:1780 -2.57% 73 Other Current Receivables is NT$5.9 Mil as of Mar. 2026. GuruFocus rates ROCO:1780 with a GF Score™ of 73/100 and a GF Value™ of NT$21.28 (Fairly Valued). The stock has 5 warning signs investors should review.

Allied Biotech's Other Current Receivables for the quarter that ended in Mar. 2026 was NT$5.9 Mil.

Allied Biotech's quarterly Other Current Receivables declined from Sep. 2025 (NT$8.32 Mil) to Dec. 2025 (NT$2.47 Mil) but then increased from Dec. 2025 (NT$2.47 Mil) to Mar. 2026 (NT$5.86 Mil).

Allied Biotech's annual Other Current Receivables declined from Dec. 2023 (NT$3.36 Mil) to Dec. 2024 (NT$2.68 Mil) and declined from Dec. 2024 (NT$2.68 Mil) to Dec. 2025 (NT$2.47 Mil).

Allied Biotech Other Current Receivables Related Terms

Allied Biotech Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Allied Biotech's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied Biotech Other Current Receivables Chart

Allied Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.39 2.40 3.36 2.68 2.47

Allied Biotech Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.43 11.25 8.32 2.47 5.86
ROCO:1780
73GF Score
Allied Biotech Corp ROCO:1780
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allied Biotech Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$5.9 Mil mean?
Allied Biotech (ROCO:1780) has a Other Current Receivables of NT$5.9 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Allied Biotech and its competitors.
Is Allied Biotech's Other Current Receivables too high?
Allied Biotech's current Other Current Receivables is NT$5.9 Mil. Overall, Allied Biotech has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Allied Biotech's Other Current Receivables compare to ZTS?
Allied Biotech's Other Current Receivables of NT$5.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Allied Biotech and its competitors. Allied Biotech's current Other Current Receivables is NT$5.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied Biotech stock overvalued right now?
Based on GuruFocus' analysis, Allied Biotech (ROCO:1780) is currently considered Fairly Valued. The stock's GF Value™ is NT$21.28, compared to a current price of NT$22.75 — trading 6.9% above its estimated fair value. The current Other Current Receivables is NT$5.9 Mil. Allied Biotech's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Allied Biotech (ROCO:1780), the current Other Current Receivables is NT$5.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Allied Biotech (ROCO:1780) Overvalued in 2026?

Based on GuruFocus' analysis, Allied Biotech stock appears to be overvalued. The current stock price of NT$22.75 is trading 6.9% above its estimated GF Value™ of NT$21.28. GuruFocus considers Allied Biotech to be Fairly Valued.

Key valuation signals for ROCO:1780:

  • Other Current Receivables: NT$5.9 Mil
  • GF Value™: NT$21.28 vs. price of NT$22.75 (6.9% above fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the ROCO:1780 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allied Biotech Business Description

Address No. 76 Tun Hua S. Road, Sec. 2, 12th Floor, Taipei, TWN
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.
73GF Score

Get the complete analysis for ROCO:1780

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.75
Price
NT$21.28
GF Value